IL-7: Phase I/IIa started

Cytheris began the open-label, French and Italian Phase I/IIa CONVERT trial in 56 patients to evaluate 3, 10, 20 and 30 µg/kg subcutaneous CYT107 plus Baraclude entecavir or Viread tenofovir with or...